cells

Domvanalimab

DOMVANALIMAB (AB154): A MONOCLONAL ANTIBODY THAT BINDS TO TIGIT, BLOCKING TUMOR IMMUNOSUPPRESSION AND INCREASING IMMUNE ACTIVITY

TIGIT-mediated signaling is known to suppress an array of anti-cancer immune cells and has been associated with poor prognosis in a variety of tumor types.

diagram

DOMVANALIMAB CLINICAL TRIALS

Non-Small Cell Lung Cancer, PD-L1 Positive (ARC-10)

A randomized Phase 3, open-label, study to evaluate the efficacy of zimberelimab (AB122) monotherapy compared to standard chemotherapy or zimberelimab combined with domvanalimab (AB154) in front-line, PD-L1-positive locally advanced or metastatic non-small cell lung cancer.

Non-small cell lung cancer, PD-L1 positive (ARC-7)

A Phase 2 trial to evaluate the safety and efficacy of zimberelimab monotherapy, domvanalimab + zimberelimab, and domvanalimab + zimberelimab + etrumadenant in front-line non-small cell lung cancer.

Multiple Cancer Types (domvanalimab + Zimberelimab)

A Phase 1b trial to evaluate the safety, tolerability, PK, PD, and clinical activity of domvanalimab ± zimberelimab in participants with advanced solid malignancies.